+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Oncology/Cancer Drugs Market By Drug Class Type, By Indication: Opportunity Analysis and Industry Forecast, 2021-2030

  • PDF Icon

    Report

  • 252 Pages
  • November 2021
  • Region: Global
  • Allied Market Research
  • ID: 5533741
The global oncology/cancer drugs market was valued at $135,494.17 million in 2020, and is projected to reach $274,400.63 million by 2030, registering a CAGR of 7.5% from 2021 to 2030.



Cancer is the uncontrolled growth of abnormal cells in the body. Cancer develops when the body’s normal control mechanism stops working. Old cells do not die and instead grow out of control, forming new, abnormal cells. The treatment of cancer in patients requires the use of different drugs like hormonal therapy, immunotherapy, targeted therapy, and chemotherapy.

Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option to treat various cancer types. Rise in incidence of various cancer conditions, increase in popularity of advance therapies (biological and targeted drug therapies), and surge in geriatric population worldwide are the key factors driving the growth of the global oncology/cancer drugs market. Furthermore, rise in cancer awareness, early screening of the cancer and availability of cancer drugs are expected to boost the market growth.

However, high cost involved in new drug development coupled with threat of failure & adverse effects associated with cancer drugs therapies is expected to restrain the growth of the market. Conversely, high potential of emerging economies and higher number of potential drugs in pipeline are expected to provide new opportunities for market players in future.

The global oncology/cancer drugs market is segmented based on drug class type, indication, and region. Depending on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy (biologic therapy), and hormonal therapy. By indication, it is categorized into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, kidney cancer, bladder cancer, and other cancers.

Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). The major companies profiled in the report include AbbVie Inc., Amgen, Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson (Janssen Global Services, LLC,), Merck & Co., Inc., Novartis AG, and Pfizer Inc.

KEY BENEFITS FOR STAKEHOLDERS

  • This report provides a detailed quantitative analysis of the current market trends and future estimations from 2020 to 2030, which assists to identify the prevailing market opportunities.
  • An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
  • A comprehensive analysis of the factors that drive and restrain the growth of the oncology/cancer drugs market is provided.
  • An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.

KEY MARKET SEGMENTS


By DRUG CLASS TYPE

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy (Biologic Therapy)
  • Hormonal Therapy

By INDICATION

  • Lung Cancer
  • Stomach Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Liver Cancer
  • Esophagus Cancer
  • Cervical Cancer
  • Kidney Cancer
  • Bladder Cancer
  • Other Cancers

By REGION

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

KEY MARKET PLAYERS

  • AbbVie Inc.
  • Amgen
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson (Janssen Global Services, LLC,)
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
Frequently Asked Questions about the Global Oncology/Cancer Drugs Market

What is the estimated value of the Global Oncology/Cancer Drugs Market?

The Global Oncology/Cancer Drugs Market was estimated to be valued at $135494.17 million in 2020.

What is the growth rate of the Global Oncology/Cancer Drugs Market?

The growth rate of the Global Oncology/Cancer Drugs Market is 7.3%, with an estimated value of $274400.63 million by 2030.

What is the forecasted size of the Global Oncology/Cancer Drugs Market?

The Global Oncology/Cancer Drugs Market is estimated to be worth $274400.63 million by 2030.

Who are the key companies in the Global Oncology/Cancer Drugs Market?

Key companies in the Global Oncology/Cancer Drugs Market include AbbVie Inc., Amgen, Astellas Pharma Inc, AstraZeneca PLC, Bristol, Myers Squibb Company, F. Hoffmann, La Roche Ltd. and Merck & Co. Inc..

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Top player positioning, 2020
3.4. Porter’s five force analysis
3.5. Clinical trials
3.6. Market dynamics
3.6.1. Drivers
3.6.1.1. Rise in incidence of cancer across the globe
3.6.1.2. Surge in the global geriatric population
3.6.1.3. Increase in government expenditure on healthcare
3.6.2. Restraint
3.6.2.1. Adverse effect associated with the use cancer drugs
3.6.3. Opportunities
3.6.3.1. High growth potential in untapped emerging economies
3.6.3.2. Increase in number of pipeline drugs
3.6.4. Impact analysis
3.7. COVID-19 Impact Analysis on Oncology/cancer Drugs Market
CHAPTER 4: ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Chemotherapy
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Targeted therapy
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. Immunotherapy
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
4.5. Hormonal therapy
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast
4.5.3. Market analysis, by country
CHAPTER 5: ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Lung Cancer
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Stomach Cancer
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Colorectal Cancer
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. Breast Cancer
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country
5.6. Prostate Cancer
5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country
5.7. Liver Cancer
5.7.1. Market size and forecast, by region
5.7.2. Market analysis, by country
5.8. Esophageal cancer
5.8.1. Market size and forecast, by region
5.8.2. Market analysis, by country
5.9. Cervical Cancer
5.9.1. Market size and forecast, by region
5.9.2. Market analysis, by country
5.10. Kidney Cancer
5.10.1. Market size and forecast, by region
5.10.2. Market analysis, by country
5.11. Bladder Cancer
5.11.1. Market size and forecast, by region
5.11.2. Market analysis, by country
5.12. Other Cancers
5.12.1. Market size and forecast, by region
5.12.2. Market analysis, by country
CHAPTER 6: ONCOLOGY/CANCER DRUGS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2.1. U.S.
6.2.2.1.1. U.S. Oncology/cancer drugs market, by drug class type
6.2.2.1.2. U.S. Oncology/cancer drugs market, By indication
6.2.2.2. Canada
6.2.2.2.1. Canada Oncology/cancer drugs market, by drug class type
6.2.2.2.2. Canada Oncology/cancer drugs market, By indication
6.2.2.3. Mexico
6.2.2.3.1. Mexico Oncology/cancer drugs market, by drug class type
6.2.2.3.2. Mexico Oncology/cancer drugs market, By indication
6.2.3. North America market size and forecast, by drug class type
6.2.4. North America market size and forecast, By indication
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Market size and forecast, by country
6.3.2.1. Germany
6.3.2.1.1. Germany Oncology/cancer drugs market, by drug class type
6.3.2.1.2. Germany Oncology/cancer drugs market, By indication
6.3.2.2. France
6.3.2.2.1. France Oncology/cancer drugs market, by drug class type
6.3.2.2.2. France Oncology/cancer drugs market, By indication
6.3.2.3. UK
6.3.2.3.1. UK Oncology/cancer drugs market, by drug class type
6.3.2.3.2. UK Oncology/cancer drugs market, By indication
6.3.2.4. Italy
6.3.2.4.1. Italy Oncology/cancer drugs market, by drug class type
6.3.2.4.2. Italy Oncology/cancer drugs market, By indication
6.3.2.5. Spain
6.3.2.5.1. Spain Oncology/cancer drugs market, by drug class type
6.3.2.5.2. Spain Oncology/cancer drugs market, By indication
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe Oncology/cancer drugs market, by drug class type
6.3.2.6.2. Rest of Europe Oncology/cancer drugs market, By indication
6.3.3. Europe market size and forecast, by drug class type
6.3.4. Europe market size and forecast, By indication
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Market size and forecast, by country
6.4.2.1. Japan
6.4.2.1.1. Japan Oncology/cancer drugs market, by drug class type
6.4.2.1.2. Japan Oncology/cancer drugs market, By indication
6.4.2.2. China
6.4.2.2.1. China Oncology/cancer drugs market, by drug class type
6.4.2.2.2. China Oncology/cancer drugs market, By indication
6.4.2.3. Australia
6.4.2.3.1. Australia Oncology/cancer drugs market, by drug class type
6.4.2.3.2. Australia Oncology/cancer drugs market, By indication
6.4.2.4. India
6.4.2.4.1. India Oncology/cancer drugs market, by drug class type
6.4.2.4.2. India Oncology/cancer drugs market, By indication
6.4.2.5. South Korea
6.4.2.5.1. South Korea Oncology/cancer drugs market, by drug class type
6.4.2.5.2. South Korea Oncology/cancer drugs market, By indication
6.4.2.6. Rest of Asia-Pacific
6.4.2.6.1. Rest of Asia-Pacific Oncology/cancer drugs market, by drug class type
6.4.2.6.2. Rest of Asia-Pacific Oncology/cancer drugs market, By indication
6.4.3. Asia-Pacific market size and forecast, by drug class type
6.4.4. Asia-Pacific market size and forecast, By indication
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. Market size and forecast, by country
6.5.2.1. Brazil
6.5.2.1.1. Brazil Oncology/cancer drugs market, by drug class type
6.5.2.1.2. Brazil Oncology/cancer drugs market, By indication
6.5.2.2. Saudi Arabia
6.5.2.2.1. Saudi Arabia Oncology/cancer drugs market, by drug class type
6.5.2.2.2. Saudi Arabia Oncology/cancer drugs market, By indication
6.5.2.3. South Africa
6.5.2.3.1. South Africa Oncology/cancer drugs market, by drug class type
6.5.2.3.2. South Africa Oncology/cancer drugs market, By indication
6.5.2.4. Rest of LAMEA
6.5.2.4.1. Rest of LAMEA Oncology/cancer drugs market, by drug class type
6.5.2.4.2. Rest of LAMEA Oncology/cancer drugs market, By indication
6.5.3. LAMEA market size and forecast, by drug class type
6.5.4. LAMEA market size and forecast, By indication
CHAPTER 7: COMPANY PROFILES
7.1. ABBVIE INC.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. AMGEN, INC.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments
7.3. ASTELLAS PHARMA INC.
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments
7.4. ASTRAZENECA PLC
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments
7.5. BRISTOL-MYERS SQUIBB COMPANY
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product Portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments
7.6. F. HOFFMANN-LA ROCHE AG
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments
7.7. JOHNSON & JOHNSON
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments
7.8. MERCK & CO., INC.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. NOVARTIS INTERNATIONAL AG
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments
7.10. PFIZER, INC.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and development
List of Tables
TABLE 01. COMPLETED CLINICAL TRIALS IN CANCER DRUGS MARKET, 2017–2021
TABLE 02. GLOBAL ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020–2030 ($MILLION)
TABLE 03. CHEMOTHERAPY ONCOLOGY/CANCER DRUGS MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 04. TARGETED THERAPY ONCOLOGY/CANCER DRUGS MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 05. IMMUNOTHERAPY ONCOLOGY/CANCER DRUGS MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 06. HORMONAL THERAPY ONCOLOGY/CANCER DRUGS MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 07. ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 08. ONCOLOGY/CANCER DRUGS MARKET FOR LUNG CANCER, BY REGION, 2020-2030 ($MILLION)
TABLE 09. ONCOLOGY/CANCER DRUGS MARKET FOR STOMACH CANCER, BY REGION, 2020-2030 ($MILLION)
TABLE 10. ONCOLOGY/CANCER DRUGS MARKET FOR COLORECTAL CANCER, BY REGION, 2020-2030 ($MILLION)
TABLE 11. ONCOLOGY/CANCER DRUGS MARKET FOR BREAST CANCER, BY REGION, 2020-2030 ($MILLION)
TABLE 12. ONCOLOGY/CANCER DRUGS MARKET FOR PROSTATE CANCER, BY REGION, 2020-2030 ($MILLION)
TABLE 13. ONCOLOGY/CANCER DRUGS MARKET FOR LIVER CANCER, BY REGION, 2020-2030 ($MILLION)
TABLE 14. ONCOLOGY/CANCER DRUGS MARKET FOR ESOPHAGEAL CANCER, BY REGION, 2020-2030 ($MILLION)
TABLE 15. ONCOLOGY/CANCER DRUGS MARKET FOR CERVICAL CANCER, BY REGION, 2020-2030 ($MILLION)
TABLE 16. ONCOLOGY/CANCER DRUGS MARKET FOR KIDNEY CANCER, BY REGION, 2020-2030 ($MILLION)
TABLE 17. ONCOLOGY/CANCER DRUGS MARKET FOR BLADDER CANCER, BY REGION, 2020-2030 ($MILLION)
TABLE 18. ONCOLOGY/CANCER DRUGS MARKET FOR OTHER CANCER, BY REGION, 2020-2030 ($MILLION)
TABLE 19. ONCOLOGY/CANCER DRUGS MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 20. NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 21. U.S. ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020–2030 ($MILLION)
TABLE 22. U.S. ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 23. CANADA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020–2030 ($MILLION)
TABLE 24. CANADA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 25. MEXICO ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020–2030 ($MILLION)
TABLE 26. MEXICO ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 27. NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020–2030 ($MILLION)
TABLE 28. NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 29. EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 30. GERMANY ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020–2030 ($MILLION)
TABLE 31. GERMANY ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 32. FRANCE ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020–2030 ($MILLION)
TABLE 33. FRANCE ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 34. UK ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020–2030 ($MILLION)
TABLE 35. UK ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 36. ITALY ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020–2030 ($MILLION)
TABLE 37. ITALY ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 38. SPAIN ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020–2030 ($MILLION)
TABLE 39. SPAIN ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 40. REST OF EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020–2030 ($MILLION)
TABLE 41. REST OF EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 42. EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020–2030 ($MILLION)
TABLE 43. EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 44. ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 45. JAPAN ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020–2030 ($MILLION)
TABLE 46. JAPAN ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 47. CHINA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020–2030 ($MILLION)
TABLE 48. CHINA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 49. AUSTRALIA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020–2030 ($MILLION)
TABLE 50. AUSTRALIA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 51. INDIA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020–2030 ($MILLION)
TABLE 52. INDIA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 53. SOUTH KOREA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020–2030 ($MILLION)
TABLE 54. SOUTH KOREA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 55. REST OF ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020–2030 ($MILLION)
TABLE 56. REST OF ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 57. ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020–2030 ($MILLION)
TABLE 58. ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 59. LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 60. BRAZIL ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020–2030 ($MILLION)
TABLE 61. BRAZIL ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 62. SAUDI ARABIA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020–2030 ($MILLION)
TABLE 63. SAUDI ARABIA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 64. SOUTH AFRICA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020–2030 ($MILLION)
TABLE 65. SOUTH AFRICA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 66. REST OF LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020–2030 ($MILLION)
TABLE 67. REST OF LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 68. LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020–2030 ($MILLION)
TABLE 69. LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 70. ABBVIE: COMPANY SNAPSHOT
TABLE 71. ABBVIE: OPERATING SEGMENTS
TABLE 72. ABBVIE: PRODUCT PORTFOLIO
TABLE 73. ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 74. AMGEN: COMPANY SNAPSHOT
TABLE 75. AMGEN: OPERATING SEGMENTS
TABLE 76. AMGEN: PRODUCT PORTFOLIO
TABLE 77. AMGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 78. ASTELLAS PHARMA: COMPANY SNAPSHOT
TABLE 79. ASTELLAS PHARMA: OERATING SEGMENT
TABLE 80. ASTELLAS PHARMA: PRODUCT PORTFOLIO
TABLE 81. ASTELLAS PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 82. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 83. ASTRAZENECA: OPERATING SEGMENTS
TABLE 84. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 85. ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 86. BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 87. BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS
TABLE 88. BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 89. ROCHE: COMPANY SNAPSHOT
TABLE 90. ROCHE: OPERATING SEGMENTS
TABLE 91. ROCHE: PRODUCT PORTFOLIO
TABLE 92. ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 93. J&J: COMPANY SNAPSHOT
TABLE 94. J&J: OPERATING BUSINESS SEGMENTS
TABLE 95. J&J: PRODUCT PORTFOLIO
TABLE 96. J&J: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 97. MERCK: COMPANY SNAPSHOT
TABLE 98. MERCK: OPERATING SEGMENTS
TABLE 99. MERCK: PRODUCT PORTFOLIO
TABLE 100. MERCK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 101. NOVARTIS: COMPANY SNAPSHOT
TABLE 102. NOVARTIS: OERATING SEGMENT
TABLE 103. NOVARTIS: PRODUCT PORTFOLIO
TABLE 104. NOVARTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 105. PFIZER: COMPANY SNAPSHOT
TABLE 106. PFIZER: OPERATING SEGMENT
TABLE 107. PFIZER: PRODUCT TYPE PORTFOLIO
TABLE 108. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
List of Figures
FIGURE 01. GLOBAL ONCOLOGY/CANCER DRUGS MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2019-2021
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2019-2021
FIGURE 06. TOP PLAYER POSITIONING, 2020
FIGURE 07. HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 08. HIGH BARGAINING POWER OF BUYERS
FIGURE 09. MODERATE THREAT OF SUBSTITUTES
FIGURE 10. HIGH THREAT OF NEW ENTRANTS
FIGURE 11. HIGH INTENSITY OF RIVALRY
FIGURE 12. IMPACT ANALYSIS
FIGURE 13. COMPARATIVE ANALYSIS OF CHEMOTHERAPY ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 14. COMPARATIVE ANALYSIS OF TARGETED THERAPY ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 15. COMPARATIVE ANALYSIS OF IMMUNOTHERAPY ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 16. COMPARATIVE ANALYSIS OF HORMONAL THERAPY ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 17. COMPARATIVE ANALYSIS OF LUNG CANCER ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020-2030 (%)
FIGURE 18. COMPARATIVE ANALYSIS OF STOMACH CANCER ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020- 2030 (%)
FIGURE 19. COMPARATIVE ANALYSIS OF COLORECTAL CANCER ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020-2030 (%)
FIGURE 20. COMPARATIVE ANALYSIS OF BREAST CANCER ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020-2030 (%)
FIGURE 21. COMPARATIVE ANALYSIS OF PROSTATE CANCER ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020- 2030 (%)
FIGURE 22. COMPARATIVE ANALYSIS OF LIVER CANCER ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020- 2030 (%)
FIGURE 23. COMPARATIVE ANALYSIS OF ESOPHAGEAL CANCER ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020- 2030 (%)
FIGURE 24. COMPARATIVE ANALYSIS OF CERVICAL CANCER ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020- 2030 (%)
FIGURE 25. COMPARATIVE ANALYSIS OF KIDNEY CANCER ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020- 2030 (%)
FIGURE 26. COMPARATIVE ANALYSIS OF BLADDER CANCER ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020- 2030 (%)
FIGURE 27. COMPARATIVE ANALYSIS OF OTHER CANCER ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020- 2030 (%)
FIGURE 28. U.S. ONCOLOGY CANCER DRUGS MARKET, 2020–2030 ($MILLION)
FIGURE 29. CANADA ONCOLOGY CANCER DRUGS MARKET, 2020–2030 ($MILLION)
FIGURE 30. MEXICO ONCOLOGY CANCER DRUGS MARKET, 2020–2030 ($MILLION)
FIGURE 31. GERMANY ONCOLOGY CANCER DRUGS MARKET, 2020–2030 ($MILLION)
FIGURE 32. FRANCE ONCOLOGY CANCER DRUGS MARKET, 2020–2030 ($MILLION)
FIGURE 33. UK ONCOLOGY CANCER DRUGS MARKET, 2020–2030 ($MILLION)
FIGURE 34. ITALY ONCOLOGY CANCER DRUGS MARKET, 2020–2030 ($MILLION)
FIGURE 35. SPAIN ONCOLOGY CANCER DRUGS MARKET, 2020–2030 ($MILLION)
FIGURE 36. REST OF EUROPE ONCOLOGY CANCER DRUGS MARKET, 2020–2030 ($MILLION)
FIGURE 37. JAPAN ONCOLOGY CANCER DRUGS MARKET, 2020–2030 ($MILLION)
FIGURE 38. CHINA ONCOLOGY CANCER DRUGS MARKET, 2020–2030 ($MILLION)
FIGURE 39. AUSTRALIA ONCOLOGY CANCER DRUGS MARKET, 2020–2030 ($MILLION)
FIGURE 40. INDIA ONCOLOGY CANCER DRUGS MARKET, 2020–2030 ($MILLION)
FIGURE 41. SOUTH KOREA ONCOLOGY CANCER DRUGS MARKET, 2020–2030 ($MILLION)
FIGURE 42. REST OF ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, 2020–2030 ($MILLION)
FIGURE 43. BRAZIL ONCOLOGY/CANCER DRUGS MARKET, 2020–2030 ($MILLION)
FIGURE 44. SAUDI ARABIA ONCOLOGY/CANCER DRUGS MARKET, 2020–2030 ($MILLION)
FIGURE 45. SOUTH AFRICA ONCOLOGY/CANCER DRUGS MARKET, 2020–2030 ($MILLION)
FIGURE 46. REST OF LAMEA ONCOLOGY/CANCER DRUGS MARKET, 2020–2030 ($MILLION)
FIGURE 47. ABBVIE: NET SALES, 2018–2020 ($MILLION)
FIGURE 48. ABBVIE: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 49. AMGEN: NET SALES, 2018–2020 ($MILLION)
FIGURE 50. AMGEN: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 51. ASTELLAS PHARMA: NET SALES, 2018–2020 ($MILLION)
FIGURE 52. ASTELLAS PHARMA: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 53. ASTRAZENECA: NET SALES, 2018–2020 ($MILLION)
FIGURE 54. ASTRAZENECA: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 55. BRISTOL-MYERS SQUIBB: NET SALES, 2018–2020 ($MILLION)
FIGURE 56. BRISTOL-MYERS SQUIBB: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 57. ROCHE: NET SALES, 2018–2020 ($MILLION)
FIGURE 58. ROCHE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 59. ROCHE: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 60. J&J: NET SALES, 2018–2020 ($MILLION)
FIGURE 61. J&J: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 62. J&J: REVENUE SHARE BY REGION, 2020(%)
FIGURE 63. MERCK: NET SALES, 2018–2020 ($MILLION)
FIGURE 64. MERCK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 65. MERCK: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 66. NOVARTIS: NET SALES, 2018–2020 ($MILLION)
FIGURE 67. NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 68. NOVARTIS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 69. PFIZER: REVENUE, 2018–2020 ($MILLION)
FIGURE 70. PFIZER: REVENUE SHARE BY REGION, 2020 (%)

Companies Mentioned

  • AbbVie Inc.
  • Amgen
  • Astellas Pharma Inc
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson (Janssen Global Services LLC)
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...